Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-4.92
Price to sales ratio
1.07

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
4445
TELA
TELA Bio, Inc. - Common stock
0.70 USD+7.69%+6.06%+1.45%-60.23%31.43 M USD
4473
MODD
Modular Medical, Inc. - common stock
3.46 USD-4.16%-1.14%+71.29%+401.45%28.20 M USD
4553
LFWD
Lifeward Ltd. - Ordinary Shares
7.46 USD+1.22%+0.40%+6.88%+1307.55%21.13 M USD
4561
PMI
Picard Medical, Inc. Common Stock
8.76 USD-3.74%+95.54%+93.81%+81.37%20.49 M USD

Frequently asked questions about Cytosorbents Corp.

What is the Cytosorbents Corp. stock price today?

The current price of Cytosorbents Corp. (CTSO) is 0.34. Over the past 24 hours, the stock has changed by 0.00%. Follow the CTSO chart for real-time price dynamics.

What is the stock ticker of Cytosorbents Corp.?

Cytosorbents Corp. trades under the ticker CTSO. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Cytosorbents Corp. stock going up?

CTSO has changed by -2.86% over the last week, -5.56% over the last month, and -63.44% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Cytosorbents Corp.?

Cytosorbents Corp. currently has a market capitalization of 21.37 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Cytosorbents Corp. earnings last quarter?

Last quarter, Cytosorbents Corp. reported earnings of -0.07 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Cytosorbents Corp. revenue for the last quarter?

Cytosorbents Corp. reported quarterly revenue of 9.63 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Cytosorbents Corp. net income for the last quarter?

Cytosorbents Corp. reported net income of -4.42 M for the last quarter. The previous quarter showed -5.13 M, which means net income changed by +13.88%.

How many employees does Cytosorbents Corp. have?

As of the latest available data, Cytosorbents Corp. has 129 employees. Workforce size can provide additional context about the company's scale and operations.

What is Cytosorbents Corp. EBITDA?

Cytosorbents Corp. EBITDA is -2 M, and its EBITDA margin is -20.72%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Cytosorbents Corp. stock?

You can buy Cytosorbents Corp. (CTSO) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Cytosorbents Corp. stock?

Investing in Cytosorbents Corp. requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the CTSO chart and related analysis on metatrader.com as part of your research.

Cytosorbents Corporation - Common Stock

CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey. CytoSorbents sells a cytokine adsorbing column — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood. The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns, which failed to show significance in a clinical trial for sepsis. The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy. Clinicaltrials.gov is giving an overview over running research projects. CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins.

News